TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 87.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,900 shares of the company's stock after selling 72,000 shares during the quarter. Handelsbanken Fonder AB's holdings in TransMedics Group were worth $666,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Yousif Capital Management LLC grew its stake in TransMedics Group by 14.6% in the 4th quarter. Yousif Capital Management LLC now owns 12,954 shares of the company's stock valued at $808,000 after acquiring an additional 1,652 shares during the period. Van ECK Associates Corp lifted its holdings in TransMedics Group by 102.3% during the fourth quarter. Van ECK Associates Corp now owns 1,997 shares of the company's stock valued at $125,000 after purchasing an additional 1,010 shares in the last quarter. Rhumbline Advisers lifted its holdings in TransMedics Group by 35.8% during the fourth quarter. Rhumbline Advisers now owns 90,061 shares of the company's stock valued at $5,615,000 after purchasing an additional 23,742 shares in the last quarter. J.W. Cole Advisors Inc. grew its position in shares of TransMedics Group by 20.7% in the fourth quarter. J.W. Cole Advisors Inc. now owns 12,384 shares of the company's stock valued at $772,000 after purchasing an additional 2,127 shares during the period. Finally, Baillie Gifford & Co. increased its stake in shares of TransMedics Group by 14.9% during the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company's stock worth $16,824,000 after purchasing an additional 34,947 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other TransMedics Group news, Director Edward M. Basile sold 5,000 shares of the company's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total transaction of $632,250.00. Following the sale, the director now owns 2,866 shares in the company, valued at $362,405.70. This represents a 63.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Anil P. Ranganath sold 686 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the sale, the insider now directly owns 13,955 shares in the company, valued at $1,950,909. This represents a 4.69% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 12,418 shares of company stock worth $1,512,613 in the last ninety days. 7.00% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Oppenheimer lifted their price target on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday. Canaccord Genuity Group restated a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Tuesday. Finally, Piper Sandler reiterated an "overweight" rating and issued a $145.00 target price (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $127.33.

TransMedics Group Trading Down 9.0%

TMDX traded down $12.20 during mid-day trading on Thursday, hitting $124.00. 2,096,632 shares of the stock were exchanged, compared to its average volume of 1,366,337. The firm's fifty day moving average is $112.41 and its two-hundred day moving average is $83.42. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The company has a market cap of $4.19 billion, a PE ratio of 91.18 and a beta of 2.10. The company has a current ratio of 9.10, a quick ratio of 8.32 and a debt-to-equity ratio of 1.92.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.41. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The business had revenue of $143.54 million for the quarter, compared to analysts' expectations of $123.39 million. During the same quarter in the prior year, the company earned $0.35 earnings per share. The business's quarterly revenue was up 48.2% on a year-over-year basis. Equities analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.